Article
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.
Nature - 1 Mar 2025
Braun David A, Moranzoni Giorgia, Chea Vipheaviny, McGregor Bradley A, Blass Eryn, Tu Chloe R, Vanasse Allison P, Forman Cleo, Forman Juliet, Afeyan Alexander B, Schindler Nicholas R, Liu Yiwen, Li Shuqiang, Southard Jackson, Chang Steven L, Hirsch Michelle S, LeBoeuf Nicole R, Olive Oriol, Mehndiratta Ambica, Greenslade Haley, Shetty Keerthi, Klaeger Susan, Sarkizova Siranush, Pedersen Christina B, Mossanen Matthew, Carulli Isabel, Tarren Anna, Duke-Cohan Joseph, Howard Alexis A, Iorgulescu J Bryan, Shim Bohoon, Simon Jeremy M, Signoretti Sabina, Aster Jon C, Elagina Liudmila, Carr Steven A, Leshchiner Ignaty, Getz Gad, Gabriel Stacey, Hacohen Nir, Olsen Lars R, Oliveira Giacomo, Neuberg Donna S, Livak Kenneth J, Shukla Sachet A, Fritsch Edward F, Wu Catherine J, Keskin Derin B, Ott Patrick A, Choueiri Toni K
Abstract excerpt
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens1-6. However, whether such responses can target cancer driver mutations, lead to immune recognition of a patient's tumour and result in clinical activity are largely unknown. These questions are of particular interest for patients who have tumours with a low mutational burden. Here we conducted a phase I...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.